

Report from Biovica's Extra Shareholder's Meeting on March 20, 2019

Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.

Below is a summary of the decisions taken at the Extra Shareholder's Meeting.

The Meeting resolved that the Chairman of the Board should be compensated with SEK 200,000 until the next Annual General Meeting.

Lars Holmqvist was elected Chairman of the Board until the end of the next Annual General Meeting.

The meeting resolved in accordance with the proposed warrant program of 175,000 options to the Board.

Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35

E-mail: anders.rylander@biovica.com

This information is information that Biovica is obliged to make public pursuant to the Nasdaq First North Rule Book. The information was submitted for publication, through the agency of the contact person set out above, at 17:00 pm CET on March 20, 2019.

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE labelled and MPA registered. Appointed Certified Adviser is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Webb www.biovica.com

Contact info@biovica.com